The company, which is eyeing growth in Italy and Spain too, going ahead, looks to launch various new products in the US market. The Hyderabad-based firm is working on plans to launch cancer treatment and injectable products in the European Union (EU). In emerging markets, the company aims to build its branded generic presence and is working on ways to deepen penetration in select markets through local manufacturing. Expanding presence in various therapeutic areas like oncology and specialty injectables is also part of the to-do list. For 2016-17, the company posted net profit of Rs 2,301.2 crore and total income of Rs 15,205.75 crore.

Source: dna July 02, 2017 05:15 UTC